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cancer with poor outcome or treatment efﬁcacy. We show that the negatively charged phospholipid
phosphatidylserine (PS) is exposed in the outer leaﬂet of their plasma membrane not only in tumor cell lines,
but also in metastases and primary cultures thereof, which contrasts with a lack of PS exposure by
differentiated non-tumorigenic counterparts. Studied tumor cell lines were derived from non-tumorigenic
and malignant melanomas, prostate- and renal cancer, glioblastoma and a rhabdomyosarcoma. Importantly,
also metastases of melanoma expose PS and there is a correlation between malignancy of melanoma cell lines
from different stages of tumor progression and PS exposure. The PS exposure we found was neither of
apoptotic nor of experimental artiﬁcial origin. Finally potentially malignant and non-malignant cells could be
differentiated by sorting of a primary cell culture derived from a glioblastoma based on PS exposure, which
has so far not been possible within one culture due to lack of a speciﬁcmarker. Our data provide clear evidence
that PS could serve as uniform marker of tumor cells and metastases as well as a target for novel therapeutic
approaches based on e.g. PS-speciﬁc host defense derived peptides.: +43 316 4120 390.
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Cancer is the leading cause of death worldwide (http://www.who.
int/mediacentre/factsheets/fs297/en/). In the last decades signiﬁcant
progress has been made in respect of diagnostics and therapeutic
approaches. However, despite favorable advancements, state of the
art chemotherapy is still not successful in many cancers. Potential
toxicity and many side effects of chemotherapeutics can mainly be
explained by a lack of adequate speciﬁcity for tumor cells. Chemo-
therapy, due to resistance and other reasons, is essentially inefﬁcient
for prostate cancer, metastatic melanoma, and bladder, kidney and
pancreatic cancer. Further, the beneﬁt of chemotherapy in general is
modest, since the increase of survival rate after 5 years for all adult
cancers is only by 2% [1]. Consistently, the search for more speciﬁc
targets generally expressed within a certain tumor is a major issue in
anti-cancer research. Cell membrane, growth factor receptors andproteins involved in cell–cell-signaling are of broad interest, but
relatively little is known about changes in lipid composition of the cell
membrane in carcinogenesis. Nevertheless, in recent years lipidomics
in cancer research has gained more attention.
The outer leaﬂet of eukaryotic plasma membranes normally
comprises neutral phospholipids, like phosphatidylcholine (PC) and
sphingomyelin (SM), whereas the negatively charged phospholipid
phosphatidylserine (PS) as well as phosphatidylethanolamine (PE)
are located in the inner leaﬂet [2]. It has been reported earlier that this
asymmetry may be lost due to reduced activity of the ATP dependent
phospholipid translocase, which speciﬁcally transports PS and PE
between bilayer leaﬂets and is susceptible to oxidative injury, or due
to the activation of a scramblase induced by increased intracellular
Ca2+ levels which leads to non-speciﬁc movement of phospholipids
[3]. This loss of asymmetry results in exposure of the negatively
charged PS on the surface of cancerous and other pathological cells
[4,5], as well as apoptotic cells [6,7] and thus PS represents a
promising target for cationic host defense peptides. The fact that
platelets and erythrocytes also expose PS upon activation [8] seems to
cause minimal side effects compared to much higher side effects
observed with other applied therapies since these peptides can act
speciﬁcally within the organism.
2639S. Riedl et al. / Biochimica et Biophysica Acta 1808 (2011) 2638–2645Surface exposure of PS by malignant cells was shown in
tumorigenic Friend erythroleukemic cells [9], other leukemia and
neuroblastoma cells [10], malignant melanoma [11] and human
gastric carcinoma cells [12]. In vivo exposure of anionic phospholipids
could be shown on the surface of endothelial cells in tumor blood
vessels [13]. In an attempt to correlate changes in the phospholipid
bilayer of malignant melanoma (MM) cell membranes with progres-
sion of these tumors Cichorek et al. showed slightly higher exposure
of PS in the more progressive amelanotic transplantable hamster cell
lines than in melanotic ones [14]. Lack of surface exposure of PS was
demonstrated for non-cancer cells as normal human epidermal
keratinocytes [11], 3T3-ﬁbroblasts [15] and lymphocytes [10].
In general, apoptotic cells exposing PS in the outer leaﬂet of the
plasma membrane are speciﬁcally recognized by macrophages [6,7]
and dendritic cells [16]. However, tumor cells, although exposing PS,
circumvent apoptosis and prevent the recognition by macrophages
[17,18]. Therefore, membrane-active peptides have been proposed to
constitute a promising approach in the development of anticancer
drugs [10,19–21]. The positively charged small peptides are produced
by the innate immune system and are able to discriminate between
different cell membranes. These host defense peptides speciﬁcally
interact with negatively charged lipids on their target cell membrane
[22–25], which would minimize side effects upon treatment and
could reach all cancer types exposing PS, even those resistant to
conventional chemotherapy.
The discovery of a speciﬁc target generally expressed within all
tumor types as well as by metastases would be a major success in
cancer research. Therefore, the present study focuses on PS exposure
of malignancies with poor outcome or treatment efﬁcacy, which
require new pharmaceutical therapies and would enormously beneﬁt
from cancer speciﬁc peptide drugs. This study has to be considered as
an extension of the pioneering work by Utsugi and coworkers [9,11]
who proved PS expression in the outer leaﬂet of three different tumor
cell lines. We extended the study by increasing the number of cancer
types and including metastases and primary cell cultures. We have
therefore clearly demonstrated that PS-exposure is a general
phenomenon not only in primary lesions of cancer but also in
metastases, cancer cell lines and primary cultures and a by far
underestimated Achilles’ heel of cancer.2. Materials and methods
2.1. Cells and culture
2.1.1. Cell lines
Glioblastoma (U87-mg) purchased from CLS (Cell Line Service
Heidelberg, Germany) and rhabdomyosarcoma cell lines (TE671)
purchased from ECAAC (Health Protection Agency Culture Collections
Salisbury, UK) were cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM, Invitrogen, UK) with addition of 2 mM glutamine, 10% FBS
(fetal bovine serum; Lot A10109-0523, PAA Laboratory, Pasching,
Austria) and 1% Pen/Strep (Penicillin/Streptomycin, PAA Laboratory,
Austria). Kidney carcinoma (769-P) and prostate adenocarcinoma cell
lines (LNCaP) purchased from CLS were cultured in RPMI1640
medium (Invitrogen, UK)with addition of 10% FBS, 2 mM L-glutamine,
1% PenStrep and 1 mM sodium pyruvate (Invitrogen, UK).
The melanocytic cell lines were kindly provided by Dr. Meenhard
Herlyn (The Wistar Institute, Philadelphia, PA). The primary human
melanoma cell lines SBcl2, WM35 and metastatic melanoma cell lines
WM9, WM164 were maintained in RPMI (Sigma, St. Louis, MO)
supplemented with 2% FBS, 2% L-glutamine and 1% Pen/Strep.
All cell lines were purchased frozen and thawed freshly before the
experiments. During culturing they were kept in a 5% CO2 atmosphere
at 37 °C. At 90% conﬂuence cell cultures were passaged with accutase
(PAA, Pasching, Austria). All cell cultures were periodically checkedfor mycoplasma and passaged in the laboratory no longer than
1 month after ﬁrst thawing.
2.1.2. Primary cell cultures
A surgical specimen of primary glioblastoma (GBM), histologically
independently veriﬁed by two pathologists (GFAP positive, Ki67 index
above 50%), was blendedmechanically and transferred to culture ﬂask
containing growth medium (DMEM, 10% FBS, 1% L-glutamine, 1% Pen/
Strep, 1% Amphotericin B; PAA Laboratory, Austria) [26]. Tumorige-
nicity has been shown in nude mice. A melanoma metastasis to the
brain (MMB), was blended mechanically and transferred to a culture
ﬂask containing growth medium (RPMI, 5% FBS, 1% L-glutamine,
1%Pen/Strep, 1% Amphotericin). Human melanocytes (FOM101), de-
rived fromhuman foreskinwere cultured inhumanmelanocytes growth
medium (PromoCell GmbH, Heidelberg, Germany). Normal human
dermal ﬁbroblasts (NHDF) purchased from PromoCell GmbH (Heidel-
berg, Germany) were cultured in ﬁbroblast growth medium 2
(PromoCell GmbH, Heidelberg, Germany).
Synoviocytes were isolated from synovium of Osteoarthritis (OA)
patients undergoing joint replacement surgery, who fulﬁlled the
criteria of the 1986 American College of Rheumatology. Random
biopsies of synovial membrane were obtained aseptically from joints
of OA patients. Synovial membrane tissue was separated macroscop-
ically from ligaments, fat and other non-synovial tissue, minced in
1 mm slices and washed with PBS (phosphate buffered saline; GIBCO
Invitrogen) supplementedwith Pen/Strep and 0.25 μg Amphotericin B
(PAA Laboratory, Austria). Synovial membrane specimens were
rinsed several times with 1× PBS, ﬁnely dissected and digested with
0.2% Collegenase B (Roche Diagnostics, Germany) in high glucose
Dulbecco's-modiﬁed Eagle's medium (DMEM-HG; GIBCO Invitrogen),
containing 10% FBS, 1% L-glutamine, Pen/Strep and Amphotericin B
(PAA Laboratory, Austria). Following overnight incubation at 37 °C,
the cell suspension was ﬁltered on a nylon membrane (Cell Strainer
40 μm; BD Bioscience). Cells were collected by centrifugation, washed
twice, re-suspended in DMEM-HG growth medium, plated in culture
ﬂasks and allowed to attach for 3 days. OA cells were authenticated by
ﬂow cytometry.
Primary culture T22 was obtained after surgical excision of a
Rhabdomyosarcoma, histologically speciﬁed by a pathologist. The
tissue was minced mechanically, washed twice and transferred to
Collagenase B and transferred to culture ﬂask containing growth
medium (DMEM-HG, 10% FBS, 1% L-glutamine, 1% Pen/Strep).
Primary cell cultures were used between passages 2 and 6 (except
for FOM101 and GBM, which were passaged up to 12). All cell cultures
were periodically checked formycoplasma. All patients consented and
ethics approval for the use of patient-derived material was given by
the local research ethics committee.
2.2. Flow cytometry analysis
2.2.1. PS exposure
For Annexin V binding cultured cells with ~90% conﬂuence were
treated with accutase for 2–3 min at 37 °C. Cells were removed gently
from the plate, dispensed into fresh media and washed once with
media. 106 cells were re-suspended in 1 ml 1× binding buffer (Abcam,
Cambridge, USA). 100 μl (105 cells) cell suspension was stained with
5 μl Annexin V-FITC and 5 μl propidium iodide (PI) (Abcam,
Cambridge, GB), i.e. incubated at room temperature for 5 min in the
dark. Flow cytometry analysis of PS-surface content of the cells was
performed with an LSRII Flow cytometer (Becton Dickinson, USA).
10.000 events were collected. Cells were identiﬁed in the side scatter
and forward scatter with linear scale. Fluorescence signal was
analyzed with logarithmic scale. Analysis was done with the FACS
Diva software (Becton Dickinson, USA). The graphical analysis was
performed in FCS-express (De Novo Software, Los Angeles, USA).
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1.5×107 primary glioblastoma cells were stained with 50 μl
Annexin V-FITC for 15 min at RT in the dark. Dead cells were
discriminated by PI staining. Annexin negative cells and Annexin
positive cells were analyzed and sorted by a live sterile cell sorting
system (BD FACSAria Cell-Sorting System BD, Biosciences, San Jose,
CA, USA).2.2.3. Apoptosis
Cleavage of caspase-3: 2×106 cells/ml were ﬁxed with formalde-
hyde for 10 min at 37 °C and permeabilized with methanol. The pellet
was re-suspended in incubation-buffer and then stained with FITC-
conjugated monoclonal active caspase-3 antibody (Cell Signaling,
USA). Cells were then analyzed by ﬂow cytometry (FACS Calibur, BD,
Biosciences, USA). Untreated cells were used as negative control. As
positive control apoptosis was induced by treatment with 10 μg/ml of
petrol ether extract of roots of the plant Onosma paniculatum [27] up
to 72 h. Analysis was performedwith CellQuest (BD, Biosciences, USA)2.3. Immunocytochemistry
After cell sorting Annexin negative and Annexin positive cells were
suspended in DMEM culture medium and seeded onto chamber slides
(BD Falcon). After overnight incubation the cells were washed with
PBS and ﬁxed with 4% formaldehyde/PBS. Staining with Ki67 (Mib-1)
antibody purchased from Ventana was performed using standardized
automated procedures with CC1 predilute antigen retrieval and
Ventana iView detection system (Ventana Medical Systems, Tucson,
AZ, USA and Dako Cytomation, Glostrup, Denmark). Counterstaining
was performed with haematoxylin.2.4. Electron microscopy
After cell sorting Annexin negative and Annexin positive cells were
separately suspended in complete DMEM culture medium, washed
with PBS, and replaced with ﬁxatives (2% paraformaldehyde, 2.5%
glutaraldehyde in 0.1 M cacodylate buffer/pH 7.4) for 30 min at RT.
Fixatives were removed and replaced with cacodylate buffer/pH 7.4
and the tissue was post ﬁxed in 2% osmium tetraoxide solution,
dehydrated in a series of graded ethanol and embedded in TAAB
epoxy resin. Sections were cut at app. 70 nm thickness, counter
stained with uranyl acetate and lead citrate, and visualized using a
Zeiss EM 902 transmission electron microscope.2.5. Fluorescence microscopy
Cells (2×104) were seeded onto 8 wells chamber slides (ibidy
GmbH, Martinsried, Germany) and grown in 300 μl medium for 2–
3 days in a conﬂuent layer. Medium was removed and cells were
washed twice with 1x Annexin binding buffer (ABB) of Vybrant
Apoptosis Assay Kit #2 (Molecular Probes™, Invitrogen). 5 μl Annexin
V-Alexa Fluor 488 (staining PS exposing cells) and 5 μl PI (staining
DNA of necrotic cells) in 300 μl ABB were added and incubated at
room temperature in the dark. After incubation cells were washed
twice with ABB to remove unbound Annexin V-Alexa Fluor 488 and
covered with ABB. A Leica DMI6000 B with IMC in connection with a
Leica DFC360 FX camera and AF 6000 software was used for imaging.
Brightﬁeld transmission, green (Annexin V-Alexa Fluor 488,
λex=488 nm and λem=530 nm) and red ﬂuorescence (PI,
λex=536 nm and λem=617 nm) were measured in the respective
channels. Exposure time, intensity and gain were ﬁxed for measure-
ment of all cell lines and primary cell cultures studied.2.6. Fluorescence spectroscopy
Cells were cultured to ~90% conﬂuence and then detached by
accutase/EDTA. Accutase activity was stopped with media containing
10% FBS. Cells were washed with 1× Annexin binding buffer (ABB) of
an Annexin V-FITC Apoptosis Detection Kit (Abcam, Cambridge, UK).
105 cells per experiment were re-suspended in 500 μl ABB and
incubated with 5 μl Annexin V-FITC and 5 μl PI for 5 min at RT in the
dark. Cells werewashedwith ABB and re-suspended in 100 μl ABB and
measured with a ﬂuorescence spectrometer (Fluoromax 3) with a
λex=488 nm and λem=530 nm. Five independent experiments were
performed.
3. Results
In the present study, we evaluated anionic phospholipids exposed
by cancer cells as targets for cationic host defense peptides and
thereof derived antitumor peptides. In particular, the speciﬁcity and
signiﬁcance of the presence of negatively charged PS in the outer
leaﬂet of the plasma membrane of tumor cells and metastases of cell
lines and primary cultures were investigated.
3.1. Cancer cells and metastases speciﬁcally and signiﬁcantly expose PS
A standard Annexin V afﬁnity assay, frequently used for detection
of apoptosis, has been applied to speciﬁcally elucidate the exposure of
PS by malignant melanoma, soft tissue, prostate, kidney and brain
cancer cell lines. However, to avoid membrane stress, adherent cells
were detached before Annexin V-FITC binding with accutase/low
EDTA instead of the standard trypsin/EDTA detachment, since
trypsinization or scrapping of the cells was shown to lead to increase
of Annexin V binding (PS exposure) (PhD thesis Maximilian Martin
Gemeinhardt, Munich, Faculty of Medicine, 2008). This is probably
due to non-repairable membrane damage.
As demonstrated by ﬂow cytometry the different cancer cell lines
of rhabdomyosarcoma, a malignant soft tissue tumor of mesenchymal
origin (TE671), prostate cancer (LNCaP), renal cell cancer (769-P)
(Fig. 1), melanoma of primary (SBcl-2, WM35) and metastatic lesions
(WM9 and WM164) and glioblastoma (U-87 mg) (Figs. 1 and 2)
exposed signiﬁcant amounts of PS compared to non-tumorigenic cells
(Fig. 1 and supplementary Fig. 1S). This is indicated by selective
binding of Annexin V-FITC to PS on the surface of tumor cells, revealed
by a strong shift in ﬂuorescence intensity of Annexin V-FITC labeled
tumor cells in contrast to unlabeled tumor cells compared to a
negligible shift of the labeled corresponding “non-tumor” control cells
like differentiated synoviocyte cells of OA patients (non-tumor
counterpart to TE671), melanocytes derived of foreskin (FOM101)
(Fig. 1) and normal human dermal ﬁbroblasts (NHDF) (supplemen-
tary Fig. 1S).
To exclude false positive results by Annexin V labeled necrotic
cells, the assays were always performed in the presence of propidium
iodide (PI) staining necrotic cells that exhibit membrane damage and
therefore also internalize Annexin V labels. Thus, PS levels referred to
are derived from Annexin positive, but PI negative cells. In types
studied, PI positive necrotic cells (Q2, supplements, Fig. 2S)
constituted only a minor population of less than 5%, whereas Annexin
positive cells (Q4, supplements, Fig. 2S) have to be ascribed to cells
exposing PS. Thus, cells studied were not undergoing necrosis. In
summary, results conﬁrmed a cancer cell speciﬁc high exposure of PS
by all the cancer cell lines investigated.
3.2. Correlation of level of PS exposure with malignancy and cancer type
To determine a possible correlation between PS exposure and
tumor progression, four human malignant melanoma (MM) cell lines
Fig. 1. Top: Flow cytometry plots of Annexin V-FITC/PI labeled (black ﬁlled) and unlabeled cells (grey line) comprising differentiated control cells of primary cell cultures (diff pcc) of
synoviocytes, isolated from synovium of Osteoarthritis (OA) patients and tumor cell lines (cl) of different cancer types, as rhabdomyosarcoma, a malignant soft tissue tumor of
mesenchymal origin (TE671), prostate cancer (LNCaP) and renal cell cancer (769-P). Plots indicate a strong binding of Annexin V to PS on tumor cell lines. Second panel: Flow
cytometry plots of Annexin V-FITC/PI labeled (black ﬁlled) and unlabeled cells (grey line) comprising differentiated control cells of primary cultures (diff pcc) of melanocytes
(FOM101) andmelanoma cell lines (cl) of primary lesions (pl) (nt non-tumorigenic) (SBcl-2) andmore highly malignant melanomametastases (met) (WM9 andWM164). Annexin
V binds signiﬁcantly to melanoma cell lines of primary and metastatic lesions. Fluorescence microscopy pictures (overlay of bright ﬁeld and ﬂuorescence channels) of melanocytes
and melanoma cell lines indicate speciﬁc binding of Annexin V-Alexa Fluor 488 (green) to PS on the outside of melanoma cells. No PI (red) is integrated assuring integrity of cells
studied.
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(Table 1).
Fluorescence spectroscopy experiments enabled a comparison of
the PS levels (Annexin V-FITC bound) exposed by different MM cell
lines (Table 1). Results revealed a correlation between tumor
malignancy and PS levels exposed. For instance, a nearly doubling in
PS exposure was observed by WM35 [28] compared to SBcl-2, a non-
tumorigenic cell line in SCIDmice [29]. In SBcl-2 cells PS exposure was
increased 4-fold compared to melanocytes whereas in cancer cells of
higher malignancy, WM9 andWM164 of metastatic lesions, exposure
was increased by 8–11 fold. Thus, a clear correlation between
malignant potential within a tumor entity and the level of PS exposed
was found. These results are in agreement with data obtained by ﬂow
cytometry (Fig. 1) (Section 3.1.) (median deviation, supplements,
Fig. 3S).
Some striking differences were observed in terms of levels of PS
exposed by other cancer types. In the case of the rhabdomyosarcoma
cell line TE671, the amount of PS exposed was signiﬁcantly higher in
comparison to malignant melanoma or 769-P cells (Table 1), whichsuggests that this cancer type may be an even better candidate for
efﬁcient treatment by PS-speciﬁc peptides.
The PS level exposed by the primary cell culture of a glioblastoma
(GBM) (see also Section 3.3.) is lower than that of melanoma cell lines
WM9 or WM164, which is quite feasible, since it is not yet a
homogenous tumor cell line. Nevertheless, the PS level is still
increased compared to melanocytes.
Fluorescence labeling of vital cells (Fig. 1) grown on slides proved
that PS (Annexin V-Alexa Fluor 488 bound, green ﬂuorescence) is
exposed by MM cells, even when not being detached before labeling
(like for ﬂow cytometry) and therefore “not stressed”, whereas non
neoplastic melanocytes showed no Annexin V binding, thus no PS
exposure. Furthermore, the quite interesting observation could be
made that PS on the surface of MM cells appeared to be clustered and
not distributed homogeneously over the plasma membrane, as would
be the case if Annexin V stained PS in the inner leaﬂet of necrotic cells.
Thus, to exclude false positive results by necrotic cells, cells were
always co-labeled with PI, but only a negligible number of PI-stained
necrotic cells were detected.
Fig. 2. Comparison of Annexin V binding by tumor cell lines and correlating primary tumor cell cultures of a rhabdomyosarcoma (T22) (correlating to rhabdomyosarcoma cell line
TE671), a glioblastoma (GBM) (correlating to glioblastoma cell line U-87 mg) and primary cell cultures of a malignant melanoma metastasis to the brain (MMB) (correlating to
melanoma cell line WM35). Flow cytometry plots of Annexin V-FITC/PI labeled cells (black ﬁlled) and unlabeled cells (grey line) comprising tumor cell lines (top) and primary cell
cultures of tumor tissue (bottom) (cl cell line; pcc primary cell culture). Tumor primary cell culture, as well signiﬁcantly expose PS indicated by Annexin V binding.
2642 S. Riedl et al. / Biochimica et Biophysica Acta 1808 (2011) 2638–26453.3. PS exposure — not an artifact of cell lines!
Cell culturing, which comprises several passages of the cells by
repeated detachment and seeding of cells, is a standard procedure for
cancer cells. The studied non-tumor cells however were primary
cultures that can only be passaged a few times. Therefore tumor cell
lines could suffer membrane damage through cell culturing pro-
cedures. In order to exclude this experimentally artiﬁcial reason for PS
exposure, in addition to studies on cancer cell lines we also
investigated primary cancer cell cultures of a glioblastoma (GBM)
(correlating to glioblastoma cell line U-87 mg), primary cells of a
rhabdomyosarcoma (T22) (correlating to rhabdomyosarcoma cell line
TE671) and a malignant melanoma metastasis to the brain (MMB)
(correlating to melanoma cell line WM35) (Fig. 2). The studied
primary tumor cells, like the cell lines showed signiﬁcant binding of
Annexin V-FITC. These results clearly indicate that not only cancer cell
lines but also primary cell cultures of malignant tumors and even
metastases expose signiﬁcant levels of PS. This further demonstrates
that PS exposure to the outer lipid leaﬂet of cancer cells is not caused
by cell culturing procedures but is an original and permanent
characteristic of cancer cells. As mentioned, it has to be taken into
account that primary cell cultures of tumors also include non
neoplastic cells with a certain extent of stromal cells and thereforeTable 1
PS exposure (Annexin V binding) of different tumor cell lines and tumor primary cell
cultures related to PS exposure of melanocytes (ﬂuorescence spectroscopy; 4
independent experiments of each cell line).
Cells Annexin V binding Absolute intensity/105 cells
Melanocytes pcca 1.0±0.4 0.31∙105
SBcl-2clb 4.1±0.6 1.28∙105
WM35 cl 7.0±1.1 2.20∙105
WM9 cl 7.6±2.1 2.38∙105
WM164 cl 11.0±3.9 3.44∙105
769-P cl 6.7±0.3 2.10∙105
TE671 cl 14.9±4.1 4.65∙105
GBM pcc 4.7±0.5 1.46∙105
apcc primary cell culture; bcl cell line.the PS level exposed can be lower compared to homogenous cancer
cell lines. This is for instance nicely demonstrated by the primary cell
culture of the melanomametastases (MMB), which shows less shift of
the Annexin V labeled cells (Fig. 2) meaning slightly reduced PS
exposure compared to melanoma cell line WM35, but still signiﬁ-
cantly increased levels compared to differentiated melanocytes
(Fig. 1).
3.4. PS — a potential common marker of cancer cells, but “no reliable eat
me” signal
There is no universal tumor marker known so far. To prove that PS
could really be an accurate marker for all cancer cells, we tried to
distinguish between tumor and non-tumor cells just by the
characteristic of exposure or non-exposure of PS, respectively.
Therefore, a primary cell culture of a histologically veriﬁed
glioblastoma (WHO grade IV) was evaluated. Even when the
specimen for the culture is obtained from the center of the tumor, it
is very likely to contain non neoplastic cells as well as glial tumor cells,
likemicroglia and stromal cells, macrophages andmaybe reactive glial
cells. A fact being of advantage in this case, since we should be able to
observe malignant and to some extent benign cell types in one
culture. Microscopic inspection of the cell culture was insufﬁcient to
distinguish between the different cell types.
After Annexin V labeling and exclusion of necrotic factors by PI,
strongly increased PS levels on the cell surface of a part of the cells
were detected. In a second step the cells were sorted using a FACS
ARIA II TM cell sorter according to their Annexin V binding events. It
was possible to obtain Annexin positive (A+) and Annexin negative
(A−) cells. These different cell types were returned to culture to let
the cells recover. The two different cultures were then investigated by
electron microscopy (Fig. 3) and immunocytochemistry using the
proliferation marker Mib-1 (Fig. 4).
The electron microscopy pictures revealed that the Annexin
positive cells (Fig. 3 C–H) (potential glial tumor cells carrying the PS
marker) showed some homogenous morphological characteristics
indicating that these cells were tumor cells. Size and shape of nuclei of
Annexin positive cells (Fig. 3 C and D) were partially changed
Fig. 3. Comparison of morphology of Annexin V negative and positive cells. Pictures are taken by a Zeiss EM 902 transmission electron microscope after sorting of an Annexin V
labeled primary culture of glioblastoma cells (GBM) by a BD FACSAria Cell-Sorting System. Annexin negative (A, B) and Annexin positive (C–H) cells are non-PS exposing and PS
exposing cells, respectively. Arrows indicate diffuse cellular border (Cell Bor), Ribosomes (Rib), (exocytosed) vesicles (Ves Ex), normal mitochondria (Mit). Annexin positive cells
show characteristics of glioblastoma (tumor) cells, but not of apoptosis.
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by an elongated or polymorphic shape and sizes up to 25 μm, which is
twice the normal size. Increased nucleus/plasma ratios, as well as
polymorphic nuclei are characteristics of tumor cells. Nevertheless,
also the few Annexin negative cells exhibited quite large nuclei (10–
15 μm), potentially representing reactive astrocytes. Furthermore, a
structural change of the plasma membrane of the Annexin positive
cells could be seen, characterized by a quite diffuse cellular border (D,
E, F, arrows Cell Bor) compared to a sharp border exhibited by
Annexin negative cells (A and B). This membrane feature is probably
reﬂecting a difference between tumor and stromal cells. Another
characteristic of the Annexin positive cells was a strong increase in
formation of ribosomes and vesicles (F and H, arrow Rib) and an
increase in exocytosis of vesicles (F, arrow Ves Ex), a feature of GBM
cells described in detail recently by Skog et al. [30]. For better
representation of intracellular changes only parts of cells are shown,
whole cell images before sorting are presented in the supplements
(Fig. 4S).
The aforementioned ﬁndings were supported by slowly growing
Annexin negative cells in contrast to well proliferating Annexin
positive cells and the fact that proliferation marker Mib-1 (Fig. 4) was
slightly higher expressed in A+ than in A− cells, a feature of
glioblastoma cells. However, it has to be noted that the amount of
Annexin negative cells within the primary cell culture was quite low.
Further the Annexin positive cells of glioblastoma were checked
for morphological changes due to apoptosis, like swelling of
mitochondria, typical apoptotic blebbing or condensation of chroma-
tin (Fig. 3 G, D, E, F, arrow Mit (normal mitochondria)). The Annexin
positive cells however were lacking all these signs of apoptosis. This
was also supported by caspase-3 cleavage assays with the melanoma
cancer cell lines used within this study (Fig. 5) revealing no signiﬁcant
caspase-3 cleavage (below 5%), thus excluding PS exposure of studiedcancer cells to be a sign of cells undergoing apoptosis. This is further
conﬁrmed by a positive control, where apoptosis was induced in the
melanoma cell line WM35 by 72 h treatment with a plant extract of
Onosma paniculatum resulting in signiﬁcant increase of caspase-3
cleavage from 2.3% by untreated up to 38% by treated cells, indicated
by a strong shift in ﬂuorescence intensity. Inducibility of cell death in a
caspase dependent manner by treatment with the plant extract was
also reported for the studiedmelanoma cell lines SBcl-2,WM35,WM9
and WM164 recently by Rinner et al. [27].
4. Discussion
After several decades of cancer research no common marker for
malignant cells has been identiﬁed so far, which would offer many
possibilities, not only for therapy, but also for fast and accurate
diagnosis. Already in 1991 Utsugi et al. [11] reported about elevated
expression of PS in the outer leaﬂet of human tumor cells. In 2002 Ran
et al. [13] showed that the monoclonal antibody 9D2 and Annexin V,
the natural ligand to anionic phospholipids, speciﬁcally localized to
tumor vessels and tumor cells in and around necrotic regions after i.v.
injection into tumor-bearing mice, whereas none of the blood vessels
in normal tissues had detectable externalized anionic phospholipids.
Our study strongly supports these ﬁndings and more importantly
clearly demonstrates that exposure of PS to the outer leaﬂet of
membranes is not restricted to blood vessels but is a general
phenomenon for cancer plasma membranes independently on cancer
type and is also valid for metastases and many cancer types including
those with poor outcome or treatability, like glioblastoma or
malignant melanoma. Thus, the anionic phospholipid PS could serve
as a common cancer marker as well as a therapeutic target. Since the
standard labeling technique with Annexin V requires an intact plasma
membrane and apoptotic or necrobiotic cells also show increased
Fig. 5. Minor caspase cleavage of melanoma cell lines. Flow cytometry plots of
melanoma cell lines were stained with FITC-conjugated monoclonal active caspase-3
antibody. Untreated cells were used as negative control. Analysis was performed with
CellQuest (BD, Biosciences, USA). No signiﬁcant cleavage of caspase-3 was detected for
untreated melanoma cell lines represented by solid lines, indicating no apoptosis. As a
positive control, WM35was treated with 10 μg/ml petrol ether extract of roots of the
plant Onosma paniculatum (OP) for 72 h (brown dashed line) [27]. Treatment caused
clear apoptosis indicated by 38% of caspase-3 cleavage.
Fig. 4. Morphology and Mib-1 immunocytochemistry of a FACS ARIA II TM cell sorted
Annexin V labeled primary cell culture of glioblastoma. Top: Annexin negative cells
(100×); bottom: Annexin positive cells (100×). Annexin positive cells express higher
levels of Mib-1.
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Therefore in our study “false positive” results by increased Annexin V
binding to PS by cells undergoing apoptosis had to be excluded. In fact,
the cancer cells tested showed elevated PS levels, but without any sign
of apoptosis. This is an important aspect, since it is mainly assumed
that cancer cells expose higher levels of PS due to their higher rate of
cell division and apoptosis, as e.g. described by Boersma et al. [31]. On
the other hand PS exposed could mean that cancer cells should be
fated to die but are clever enough to avoid the last step of being killed.
As mentioned earlier there are several ways for cancer cells to prevent
apoptosis like melanoma cells inhibiting the expression of the gene
encoding Apaf-1, the apoptotic protease activating factor-1 [17].
It is not fully understood how and why cancer cells expose PS to
the outer plasma membrane leaﬂet. When separating phospholipids
of a total cell lipid extract of human melanocytes (FOM101) and two
melanoma cell lines (SBcl-2 and WM164) by two-dimensional thin-
layer chromatography and quantiﬁcation by the method of Broe-
khuyse [32], no increase in the total amount of PS was found in the
cancer cells (data not shown). Therefore, not the overall PS content
but only the asymmetric PS distribution in the plasma membrane
seems to get lost. It has been reported that the combined action of an
amino phospholipid translocase, responsible for the speciﬁc move-
ment of PS and PE to the inner leaﬂet of plasmamembranes, and a less
speciﬁc ﬂoppase, responsible for the movement of PS and PC to the
outside, both dependent on ATP, seems to equip the cell with a
mechanism that corrects for alterations in lipid distribution to avoid
potential pathological consequences [5]. Nevertheless, as reported,
inactivation of these activities in vitro did not result in loss of
asymmetry. However, activation of a third protein, the lipid
scramblase, by inﬂux of Ca2+ into the cytoplasm can cause a rapid
transbilayer phospholipid mixing leading to a nearly symmetricdistribution across the membrane bilayer [5]. Thus, cellular changes
like depletion of ATP and/or inﬂux of Ca2+ into the cytoplasm seem to
be important factors accounting for exposure of PS. Furthermore, it
has been proposed by Ran et al. [13] that injury and activation of
tumor endothelium by cytokines and reactive oxygen species might
induce PS exposure of tumor vessels. As mentioned in Section 3.2., we
were able to observe by ﬂuorescence microscopy that PS, visualized
by Annexin V-Alexa Fluor 488, was localized in clusters on the plasma
membrane of cancer cells. Interestingly some of these PS exposing
clusters budded off the cells were quite mobile and even moved from
one cell to the other in the form of small PS exposing blebs
(unpublished observation). In this context it is of interest to note
that loss of membrane asymmetry is often accompanied by blebbing
and subsequent shedding of lipid-symmetric microvesicles from the
cell surface [33,34]. It is known that eukaryotic cells are able to
perform intercellular communication by e.g., exosomes [35]. If these
vesicles still carry the PS marker, one could then assume that host
defense peptides, which can target PS would also be able to prevent
possible intercellular communication between cancer cells.
Deﬁnitely, PS constitutes an Achilles' heel of cancer cells, because
the anionic lipid represents a cancer type independent target for host
defense peptides that rapidly kill cells exposing negatively charged
lipids. A number of studies revealed that cationic amphipathic
peptides speciﬁcally interact with PS containing membranes [10,36–
38]. So far highly active antimicrobial peptides derived from host
defense could be designed to selectively target bacterial membranes
[39–43], whereas antitumor peptides to target cancer cell membranes
are in development [20,24,37,44,45]. The high levels of exposed PS
found in our study for cancer cell lines, derived from metastatic
lesions, suggest that these peptides can even be beneﬁcial as a
therapeutic intervention in the metastatic cascade, which is difﬁcult
so far. Furthermore, all cancer types including cancer with poor
prognosis and treatability, like glioblastoma and melanoma, amongst
others, would highly beneﬁt using the PS target for novel approaches
in diagnosis and therapy. Successful sorting of a primary culture of a
glioblastoma within this study gives hope for possible differentiation
between tumor and non-tumor cells and selective targeted therapy.
Conclusions
Our study constitutes an extension of previous work [11] regarding
cancer types with a focus on cancer with poor outcome and treatment
efﬁcacy, including metastases and primary cell cultures using another
assay.We show that PS exposure is also a characteristic of metastases, a
2645S. Riedl et al. / Biochimica et Biophysica Acta 1808 (2011) 2638–2645very important aspect regarding therapy. Furthermore, we compared
several primary cancer cell cultures with correlating cell lines to rule
out cell culturing effects on themembrane and to prove originality of PS
exposure. Cancer speciﬁc PS exposure was not a sign of apoptosis. By
using PS as a marker it was possible to distinguish within a primary
culture of glioblastoma between potential malignant and benign cells.
The study aimed at supplying evidence for a uniform and novel
target for cancer therapy in the form of the negatively charged lipid
phosphatidylserine.We prove that PS is speciﬁcally exposed by cancer
cells andmetastases, which delivers the important basis and target for
the further development of cationic antitumor peptide drugs, to one
day support or even partially substitute chemotherapy.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamem.2011.07.026.
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